Pharmacological management of migraine: current strategies and future directions

References

• Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev. 2023;103(2):1565–1644. doi: 10.1152/physrev.00059.2021
   PubMed Web of Science ®Google Scholar
• Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019;25(2 Suppl):S23–S34.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Goadsby PJ. Discovery of CGRP in relation to migraine. Cephalalgia. 2019;39(3):331–332. doi: 10.1177/0333102418779544
   PubMed Web of Science ®Google Scholar
• Sacco S, Amin FM, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23(1):67. doi: 10.1186/s10194-022-01431-x
   PubMed Web of Science ®Google Scholar
• Haghdoost F, Puledda F, Garcia-Azorin D, et al. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43(4):3331024231159366. doi: 10.1177/03331024231159366
   Web of Science ®Google Scholar
• Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–514. doi: 10.1038/s41582-021-00509-5
   PubMed Web of Science ®Google Scholar
• American Headache Society. The American headache society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18. doi: 10.1111/head.13456
   PubMed Web of Science ®Google Scholar
• Ailani J, Burch RC, Robbins MS, et al. The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–1039. doi: 10.1111/head.14153
   PubMed Web of Science ®Google Scholar
• Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD010210. doi: 10.1002/14651858.CD008040.pub3. PMID: 23633349; PMCID: PMC6483792.
   PubMed Web of Science ®Google Scholar
• Kirthi V, Derry S, Moore RA, et al. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008041. doi: 10.1002/14651858.CD008041.pub2. PMID: 20393963; PMCID: PMC4163048.
   PubMed Web of Science ®Google Scholar
• Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;2013(4):CD008039. doi: 10.1002/14651858.CD008039.pub3
   PubMedGoogle Scholar
• Law S, Derry S, Moore RA. Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;2013(10):CD009455. doi: 10.1002/14651858.CD009455.pub2
   PubMedGoogle Scholar
• Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2012;2(2):CD008783.
   PubMedGoogle Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20. doi: 10.1111/head.12499
   PubMed Web of Science ®Google Scholar
• Dahlöf CG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans - review of four trials. Cephalalgia. 2006;26(2):98–106. doi: 10.1111/j.1468-2982.2005.01010.x
   PubMed Web of Science ®Google Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev. 2014;2014(5):CD009108. doi: 10.1002/14651858.CD009108.pub2
   PubMedGoogle Scholar
• Lipton RB, Munjal S, Brand-Schieber E, et al. DFN-02 (sumatriptan 10 mg with a permeation enhancer) nasal spray vs placebo in the acute treatment of migraine: a double-blind, placebo-controlled study. Headache. 2018;58(5):676–687. doi: 10.1111/head.13309
   PubMed Web of Science ®Google Scholar
• Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst Rev. 2016;4(4):CD008541. doi: 10.1002/14651858.CD008541.pub3
   PubMedGoogle Scholar
• Petersen CL, Hougaard A, Gaist D, et al. Risk of stroke and myocardial infarction among initiators of triptans. JAMA Neurol. 2024;81(3):248–254. doi: 10.1001/jamaneurol.2023.5549
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC. Delayed absorption of many (paracetamol, aspirin, other NSAIDs and zolmitriptan) but not all (sumatriptan, rizatriptan) drugs during migraine attacks and most likely normal gastric emptying outside attacks. A review. Cephalalgia. 2017;37(9):892–901. doi: 10.1177/0333102416644745
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Pharmacological strategies to treat attacks of episodic migraine in adults. Expert Opin Pharmacother. 2021;22(3):305–316. doi: 10.1080/14656566.2020.1828347
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia. 2008;28(8):877–886. doi: 10.1111/j.1468-2982.2008.01578.x
   PubMed Web of Science ®Google Scholar
• Smith TR, Winner P, Aurora SK, et al. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, precision olfactory delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 2021;61(8):1214–1226. doi: 10.1111/head.14184
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC, Pihl T, Hougaard A, et al. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert Opin Investig Drugs. 2014;23(3):375–385. doi: 10.1517/13543784.2014.861817
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain. 2009;142(3):179–182. doi: 10.1016/j.pain.2009.01.013
   PubMed Web of Science ®Google Scholar
• Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–981. doi: 10.1111/j.1468-1331.2009.02748.x
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Prophylactic pharmacotherapy of migraine. Some practical guidelines. Neurol Clin. 1997;15(1):153–165. doi: 10.1016/S0733-8619(05)70301-7
   PubMed Web of Science ®Google Scholar
• Schytz HW, Amin FM, Jensen RH, et al. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish headache society, 3rd edition, 2020. J Headache Pain. 2021;22(1):22.
   PubMed Web of Science ®Google Scholar
• Danesh A, Gottschalk PCH. Beta-blockers for migraine prevention: a review article. Curr Treat Options Neurol. 2019;21(4):20. doi: 10.1007/s11940-019-0556-3
   PubMed Web of Science ®Google Scholar
• Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289(1):65–69. doi: 10.1001/jama.289.1.65
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Linde M, Gravdahl GB, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;34(7):523–532. doi: 10.1177/0333102413515348
   PubMed Web of Science ®Google Scholar
• Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001;322(7277):19–22. doi: 10.1136/bmj.322.7277.19
   PubMedGoogle Scholar
• Linde M, Mulleners WM, Chronicle EP, et al. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;2013(6):CD010610.
   PubMed Web of Science ®Google Scholar
• Linde M, Mulleners WM, Chronicle EP, et al. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;2013(6):CD010611. doi: 10.1002/14651858.CD010611
   PubMedGoogle Scholar
• Lampl C, Versijpt J, Amin FM, et al. European headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 1: amitriptyline. J Headache Pain. 2023;24(1):39. doi: 10.1186/s10194-023-01573-6
   PubMed Web of Science ®Google Scholar
• Xu XM, Liu Y, Dong MX, et al. Tricyclic antidepressants for preventing migraine in adults. Medicine (Baltimore). 2017;96(22):e6989. doi: 10.1097/MD.0000000000006989
   PubMed Web of Science ®Google Scholar
• Xu XM, Yang C, Liu Y, et al. Efficacy and feasibility of antidepressants for the prevention of migraine in adults: a meta-analysis. Eur J Neurol. 2017;24(8):1022–1031. doi: 10.1111/ene.13320
   PubMed Web of Science ®Google Scholar
• Jackson JL, Cogbill E, Santana-Davila R, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLOS ONE. 2015;10(7):e0130733. doi: 10.1371/journal.pone.0130733
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803. doi: 10.1177/0333102410364676
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–814. doi: 10.1177/0333102410364677
   PubMed Web of Science ®Google Scholar
• Pijpers JA, Kies DA, Louter MA, et al. Acute withdrawal and botulinum toxin a in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain. 2019;142(5):1203–1214. doi: 10.1093/brain/awz052
   PubMedGoogle Scholar
• Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin a for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307(16):1736–1745. doi: 10.1001/jama.2012.505
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene–related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–1110. doi: 10.1056/NEJMoa030505
   PubMed Web of Science ®Google Scholar
• Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1):37. doi: 10.1186/s10194-019-0974-3
   PubMedGoogle Scholar
• Charles AC, Digre KB, Goadsby PJ, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American headache society position statement update. Headache. 2024 Mar 11;64(4):333–341. doi:10.1111/head.14692. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Drellia K, Kokoti L, Deligianni CI, et al. Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia. 2021;41(7):851–864. doi: 10.1177/0333102421989601
   PubMed Web of Science ®Google Scholar
• Wang X, Wen D, He Q, et al. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. J Headache Pain. 2022;23(1):105. doi: 10.1186/s10194-022-01472-2
   PubMed Web of Science ®Google Scholar
• Tinsley A, Rothrock JF. Safety and tolerability of preventive treatment options for chronic migraine. Expert Opin Drug Saf. 2021;20(12):1523–1533. doi: 10.1080/14740338.2021.1942839
   PubMed Web of Science ®Google Scholar
• Aleksovska K, Hershey AD, Deen M, et al. Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the international headache society. Cephalalgia. 2023;43(10):3331024231206162. doi: 10.1177/03331024231206162
   Web of Science ®Google Scholar
• Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42(2):108–118. doi: 10.1177/03331024211053571
   PubMed Web of Science ®Google Scholar
• Ashina M, Goadsby PJ, Reuter U, et al. Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019;39(11):1455–1464. doi: 10.1177/0333102419854082
   PubMed Web of Science ®Google Scholar
• Sakai F, Suzuki N, Ning X, et al. Long-term safety and tolerability of fremanezumab for migraine preventive treatment in Japanese outpatients: a multicenter, randomized, open-label study. Drug Saf. 2021;44(12):1355–1364. doi: 10.1007/s40264-021-01119-2
   PubMed Web of Science ®Google Scholar
• Kudrow D, Cady RK, Allan B, et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC neurol. 2021;21(1):126. doi: 10.1186/s12883-021-02123-w
   PubMed Web of Science ®Google Scholar
• Pozo-Rosich P, Detke HC, Wang S, et al. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin. 2022;38(5):731–742. doi: 10.1080/03007995.2022.2059975
   PubMed Web of Science ®Google Scholar
• Pavelic AR, Wöber C, Riederer F, et al. Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data. Cells. 2022;12(1):143. doi: 10.3390/cells12010143
   PubMed Web of Science ®Google Scholar
• Iannone LF, Fattori D, Benemei S, et al. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol. 2022;29(5):1505–1513. doi: 10.1111/ene.15260
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–2241. doi: 10.1056/NEJMoa1813049
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant versus placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–1898. doi: 10.1001/jama.2019.16711
   PubMed Web of Science ®Google Scholar
• Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51–60. doi: 10.1016/S0140-6736(20)32544-7
   PubMed Web of Science ®Google Scholar
• Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695–706. doi: 10.1056/NEJMoa2035908
   PubMed Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209–217. doi: 10.1016/S1474-4422(22)00517-8
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Nagy K, Pozo-Rosich P, et al. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024;23(4):382–392. doi: 10.1016/S1474-4422(24)00025-5
   PubMed Web of Science ®Google Scholar
• Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10404):775–785. doi: 10.1016/S0140-6736(23)01049-8
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Schwedt TJ, et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023;402(10419):2307–2316. doi: 10.1016/S0140-6736(23)01683-5
   PubMed Web of Science ®Google Scholar
• Christensen RH, Eigenbrodt AK, Ashina H, et al. What proportion of people with migraine report postdromal symptoms? A systematic review and meta-analysis of observational studies. Cephalalgia. 2023;43(10):3331024231206376. doi: 10.1177/03331024231206376
   Web of Science ®Google Scholar
• Navratilova E, Behravesh S, Oyarzo J, et al. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia. 2020;40(9):892–902. doi: 10.1177/0333102420938652
   PubMed Web of Science ®Google Scholar
• Schwedt TJ, Myers Oakes TM, Martinez JM, et al. Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: results from a randomized, controlled clinical trial. Neurol Ther. 2024;13(1):85–105. doi: 10.1007/s40120-023-00562-w
   PubMed Web of Science ®Google Scholar
• Jakate A, Blumenfeld AM, Boinpally R, et al. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: a randomized phase 1b drug-drug interaction study. Headache. 2021;61(4):642–652. doi: 10.1111/head.14095
   PubMed Web of Science ®Google Scholar
• Chaudhari K, Syed BA. The pipeline and market for migraine drugs. Nat Rev Drug Discov. 2023 Nov 17;23(4):246–247. doi: 10.1038/d41573-023-00182-x
   Web of Science ®Google Scholar
• Pellesi L, Ashina M, Martelletti P. Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention. Expert Opin Emerg Drugs. 2024;29(1):57–64. doi: 10.1080/14728214.2024.2317778
   PubMed Web of Science ®Google Scholar
• Guan LC, Dong X, Green DP. Roles of mast cells and their interactions with the trigeminal nerve in migraine headache. Mol Pain. 2023;19:17448069231181358. doi: 10.1177/17448069231181358
   Web of Science ®Google Scholar
• Rasmussen NB, Deligianni C, Christensen CE, et al. The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study. J Headache Pain. 2023;24(1):60. doi: 10.1186/s10194-023-01599-w
   PubMed Web of Science ®Google Scholar
• Ashina M Efficacy and safety of Lu AG09222 for migraine prevention in patients with 2-4 previous preventive treatment failures: HOPE, an interventional, randomized, double-blind, parallel-group, placebo-controlled phase 2 trial. Presented at the International Headache Congress; 2023 Sep 14-17; Seoul (South Korea).
   Google Scholar
• Worm J, Falkenberg K, Olesen J. Histamine and migraine revisited: mechanisms and possible drug targets. J Headache Pain. 2019;20(1):30. doi: 10.1186/s10194-019-0984-1
   PubMedGoogle Scholar
• Kandasamy R, Dawson CT, Craft RM, et al. Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat. Eur J Pharmacol. 2018;818:271–277. doi: 10.1016/j.ejphar.2017.10.054
   PubMed Web of Science ®Google Scholar
• Greco R, Mangione AS, Sandrini G, et al. Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. J Headache Pain. 2014;15(1):14. doi: 10.1186/1129-2377-15-14
   PubMed Web of Science ®Google Scholar
• Szewczyk AK, Ulutas S, Aktürk T, et al. Prolactin and oxytocin: potential targets for migraine treatment. J Headache Pain. 2023;24(1):31. doi: 10.1186/s10194-023-01557-6
   PubMed Web of Science ®Google Scholar
• Tzabazis A, Kori S, Mechanic J, et al. Oxytocin and migraine headache. Headache. 2017;57 Suppl 2(S2):64–75. doi: 10.1111/head.13082
   PubMedGoogle Scholar
• Coronel MF, Labombarda F, González SL. Neuroactive steroids, nociception and neuropathic pain: a flashback to go forward. Steroids. 2016;110:77–87. doi: 10.1016/j.steroids.2016.04.005
   PubMed Web of Science ®Google Scholar
• Li Z, Ramirez G, Tang R, et al. Modeling digestion, absorption, and ketogenesis after administration of tricaprilin formulations to humans. Eur J Pharm Biopharm. 2023;182:41–52. doi: 10.1016/j.ejpb.2022.11.022
   PubMed Web of Science ®Google Scholar
• Chiang CC, Arca KN, Dunn RB, et al. Real-world efficacy, tolerability, and safety of ubrogepant. Headache. 2021;61(4):620–627. doi: 10.1111/head.14062
   PubMed Web of Science ®Google Scholar
• Varnado OJ, Hoyt M, Ye W, et al. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication. Curr Med Res Opin. 2022;38(8):1451–1457. doi: 10.1080/03007995.2022.2091333
   PubMed Web of Science ®Google Scholar
• Pellesi L. Combining two CGRP inhibitors to treat migraine. Expert Opin Drug Saf. 2022;21(9):1135–1136. doi: 10.1080/14740338.2022.2130890
   PubMed Web of Science ®Google Scholar
• Siersbæk N, Kilsdal L, Jervelund C, et al. Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine. BMC neurol. 2023;23(1):254. doi: 10.1186/s12883-023-03302-7
   PubMed Web of Science ®Google Scholar
• Autio H, Purmonen T, Kurki S, et al. Erenumab decreases headache-related sick leave days and health care visits: a retrospective real-world study in working patients with migraine. Neurol Ther. 2022;11(1):223–235. doi: 10.1007/s40120-021-00303-x
   PubMed Web of Science ®Google Scholar
• Pozo-Rosich P, Poveda JL, Crespo C, et al. Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis. J Headache Pain. 2024;25(1):40. doi: 10.1186/s10194-024-01747-w
   PubMed Web of Science ®Google Scholar
• Bjornsdottir G, Chalmer MA, Stefansdottir L, et al. Rare variants with large effects provide functional insights into the pathology of migraine subtypes, with and without aura. Nat Genet. 2023;55(11):1843–1853. doi: 10.1038/s41588-023-01538-0
   PubMed Web of Science ®Google Scholar
• Ashina M, Terwindt GM, Al-Karagholi MA, et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet. 2021;397(10283):1496–1504. doi: 10.1016/S0140-6736(20)32162-0
   PubMed Web of Science ®Google Scholar